trending Market Intelligence /marketintelligence/en/news-insights/trending/vsgM1qNNA60svNgxOVQ2zA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Repros Therapeutics not eligible for extra time to regain Nasdaq compliance

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Repros Therapeutics not eligible for extra time to regain Nasdaq compliance

Nasdaq Stock Market LLC notified Repros Therapeutics Inc. that due to continued noncompliance with the minimum bid price rule, the company is not eligible for an additional 180-day extension to regain compliance.

Further, the determination serves as an additional basis for delisting the company's securities from the exchange.

The current notice has no effect on the listing of the company's common stock.

The company has also been noncompliant with the minimum stockholders' equity requirement, and had earlier requested a hearing before the Nasdaq hearings panel. An oral hearing is set for Jan. 18, 2018.